BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ISIS-CRPRx: Phase I data

Data from the cohort of 8 subjects with elevated baseline CRP levels (3 mg/L) in a double-blind, dose-escalation Phase I trial showed that weekly 600 mg ISIS-CRPRx significantly reduced CRP levels by >70% vs. placebo after only 3...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >